Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
Immunic, Inc. received an amended Schedule 13G/A from Aberdeen Group plc and its subsidiary abrdn Inc. reporting a significant ownership position in the company’s common stock.
The filing shows beneficial ownership of 8,243,941 Immunic common shares, representing 6.85% of the class as of 12/31/2025. Both Aberdeen Group plc and abrdn Inc. report shared power to vote and dispose of these shares, with no sole voting or dispositive power.
The securities are stated to be acquired and held in the ordinary course of business, and not for the purpose of changing or influencing control of Immunic. Aberdeen Group plc is identified as the parent company, with abrdn Holdings Limited as intermediate holding company for abrdn Inc.
Immunic, Inc. is moving its common stock listing from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective at the opening of business on January 7, 2026, while continuing to trade under the symbol IMUX.
The company previously fell out of compliance with Nasdaq’s $1.00 minimum bid price rule and did not regain compliance by the initial December 24, 2025 deadline, triggering this transfer request. With Nasdaq’s approval, Immunic now has an additional 180 days, until June 22, 2026, for its common stock to maintain a minimum $1.00 bid price for at least 10 consecutive business days to regain compliance. As a condition of this extension, Immunic has notified Nasdaq that it will seek to implement a reverse stock split, if needed, and faces potential delisting if compliance is not achieved and any subsequent appeal is unsuccessful.
Immunic, Inc. furnished a current report to note that it has issued a press release announcing its financial results for the quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1 to the report, but the company specifies that this information is being furnished, not filed, so it is not subject to certain liability provisions of the securities laws or automatically incorporated into other SEC filings.
Immunic, Inc. filed its Q3 2025 report, highlighting continued losses and liquidity pressure. The company reported a net loss of $25,579 for the quarter and $77,872 for the nine months ended September 30, 2025. Cash and cash equivalents were $35,132, while net cash used in operating activities reached $66,525 for the nine-month period.
Current liabilities were $30,079 against total stockholders’ equity of $10,499, down from $18,429 at year-end. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. During 2025, Immunic raised $60,661 from a May offering and $4,734 from an April offering to fund operations. The company also received a Nasdaq notice for failure to maintain the $1.00 minimum bid, with a compliance window through December 24, 2025. Immunic continues advancing late-stage oral therapies, including vidofludimus calcium in Phase 3 for relapsing multiple sclerosis.
Immunic, Inc. announced presentations of vidofludimus calcium data at the 41st ECTRIMS congress in Barcelona, held September 24-26, 2025. The company issued a press release dated September 25, 2025, and posted a corporate presentation on its website on September 24, 2025, which includes new data from the Phase 2 CALLIPER trial in progressive multiple sclerosis. The filing lists the press release and the presentation as exhibits and states the report was signed by CEO Daniel Vitt.
Immunic, Inc. is registering 7,000,000 additional shares of common stock for issuance under its 2019 Omnibus Equity Incentive Plan, as amended. On April 20, 2025, the board approved an amendment to the plan, subject to stockholder approval, to raise the total shares authorized for issuance under the plan to 26,448,871. Stockholders approved this amendment on June 4, 2025, and this Form S-8 filing implements that approval.
The newly registered shares are of the same class as those covered by prior Form S-8 registrations and will be issuable to eligible participants in the 2019 plan. Immunic also restates its standard Delaware-law based indemnification and director-and-officer insurance protections for its directors and officers in connection with securities law liabilities.
Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh report beneficial ownership equal to 9.9% of Immunic, Inc. common stock on a fully‑diluted, exercise‑limited basis. The filing discloses that the reporting persons hold warrants to purchase 11,250,000 shares but, due to exercise limitations in the warrant terms, may only exercise for up to 9,485,936 shares, representing 9.9% of the issuer based on 95,817,536 outstanding shares. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Nantahala Capital Management, LLC and two individuals report a 9.99% beneficial interest in Immunic, Inc. The filing shows Nantahala, together with Wilmot B. Harkey and Daniel Mack, may be deemed the beneficial owners of 10,634,565 shares of Immunic common stock, representing 9.99% of the class as of June 30, 2025. The amount reported includes shares that may be acquired within 60 days through exercise of warrants. The Reporting Persons disclose shared voting and dispositive power over these shares and identify BLACKWELL PARTNERS LLC - SERIES A as a fund with the right to receive dividends or sale proceeds for more than 5% of the shares reported. The filing certifies the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control.
Biotechnology Value Fund and related entities reported combined beneficial ownership in Immunic, Inc. As of June 30, 2025 the Reporting Persons and a Partners managed account held 8,580,151 pre-funded warrants exercisable for shares and 13,335,000 new pre-funded warrants accompanied by Series A and Series B warrants. After applicable exercise blockers, BVF beneficially owned 6,268,162 shares (approximately 6.4%), BVF2 owned 3,027,105 shares (approximately 3.2%), Trading Fund OS owned 315,231 shares (0.3%) and certain aggregate entities may be deemed to own between 9.5% and 9.99% of outstanding shares. Series A and B warrants have a $0.75 exercise price; Series A expire December 31, 2025, Series B expire five years from issuance and have conditions tied to a $1.25 VWAP target. Multiple vehicles disclaim ownership of others' holdings; exercise is limited by contractual 9.9%/9.99% blockers.
Avidity-related reporting persons disclosed an aggregate 5,615,811 share position in Immunic, Inc. (IMUX), equal to 5.9% of the outstanding common stock, held with shared voting and dispositive power. The filing shows no reporting person claims sole voting or dispositive authority over these shares. A separate entity, Avidity Private Master Fund I LP, is shown with 4,699,411 shares (4.9%).
The statement explains the reported securities are directly owned by advisory clients of Avidity Partners Management LP and that none of those advisory clients may be deemed to beneficially own more than 5% of the class. The reporting persons include a disclaimer of beneficial ownership except to the extent of pecuniary interest and certify the holdings were not acquired to change or influence control of the issuer.